|Bid||84.00 x 1100|
|Ask||0.00 x 1800|
|Day's Range||83.58 - 87.19|
|52 Week Range||79.13 - 106.74|
|Beta (3Y Monthly)||1.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.46|
When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.
Biotech stocks are on track to extend their losses, bucking the positive broader market sentiment. The week saw Achaogen Inc (NASDAQ: AKAO ) filing for Chapter 11 bankruptcy and negative clinical readouts ...
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN RAFAEL, Calif., April 17, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51st on last year's 2018 list. BioMarin was ranked first among its peers in the 'Drugs & Biotechnology' industry. "We are honored to again be named one of Forbes Best Employers.
The Nasdaq 100 just hit a record, but that doesn't mean buying tech is off the table, one expert says. The tech-heavy index made an all-time high Wednesday morning, helped by a 4% surge in shares of Intel INTC . "I think Intel had the most constructive pullback to those December lows, which was a double bottom," Baruch said Tuesday on CNBC's "Trading Nation," pointing to the semiconductor company's three-year chart.
Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.
A small handful of the Bay Area's largest tech employers, including Facebook, Palo Alto Networks, Splunk and Broadcom, pay their median employee above $200,000 per year.
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding BMRN is favorable, with net inflows of $114.25 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.
Tesla last year awarded CEO Elon Musk a stock options package worth $2.28 billion — which works out to some 40,668 times more than what the company’s median worker earns in a year.
SAN RAFAEL, Calif. , April 2, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 32.04% for BioMarin Pharmaceutical (BMRN) based on the stock’s
Even in development-averse Marin, new hotel proposals are being stuffed into the Bay Area pipeline in an effort to meet accelerating demand.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...